Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel treatment options for metabolic disorders described in recent Merck and Dainippon patents

Aug. 22, 2006

TolerRx raises funding to develop TRX-4

Aug. 22, 2006

Alantos begins phase I study with ALS 2-0426

Aug. 22, 2006

Rhucin MAA accepted for review

Aug. 21, 2006

Actonel approved for men with osteoporosis

Aug. 21, 2006

Recent Tanabe and Dainippon patents describe new antidiabetic agents

Aug. 21, 2006

Galvus filed for European approval in type 2 diabetes

Aug. 17, 2006

Nastech studies PYY3-36 nasal spray in dose-ranging obesity study

Aug. 17, 2006

Acrux and Population Council amend transdermal contraceptive agreement

Aug. 17, 2006

U.K. clearance for phase I study of obesity drug ATHX-105

Aug. 16, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...